ArticlesAzithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial
Introduction
Acute exacerbations of chronic obstructive pulmonary disease (COPD) have important implications for the natural course of COPD and cause high mortality rates in patients with COPD.1 Patients with three or more exacerbations for which hospital admission is needed have a risk of mortality that is four times higher than those with no exacerbations.2 Prevention of exacerbations is therefore an essential strategy, not only for improvement of mortality rates, but also for improvement of health-related quality of life3 and deceleration of further decline of lung function in patients with COPD.4
Prevention of acute exacerbations of COPD with long-term macrolide treatment is a recent development and the beneficial effect of this treatment has been postulated to result from both an antimicrobial and an immunomodulatory effect.5 The largest study to date of this approach showed that long-term treatment with daily azithromycin significantly decreased the frequency of acute exacerbations of COPD.6 However, this study included patients with at least one exacerbation within the previous year and those who were receiving continuous supplemental oxygen without having had any exacerbation. Implementation of this strategy in clinical practice might result in an excessive use of macrolides in patients with COPD. However, the main risk of the increasing consumption of azithromycin is the induction of macrolide resistance in a large group of patients, with the additional risk of induction of resistance to the general population.7 To benefit maximally from macrolide treatment and to reduce the risk of resistance simultaneously, restrictive use of azithromycin is presently warranted.7 Proposals have been made to reserve long-term macrolide treatment for patients with two or more COPD exacerbations;7, 8 however, this recommendation was not supported by findings from clinical studies.
We did the COpd: infLUence of Macrolides on exacerBation freqUency in patientS (COLUMBUS) trial to investigate whether patients with COPD who had three or more exacerbations in the previous year would have a decreased rate of exacerbation when maintenance macrolide treatment was added to standard care.
Section snippets
Study design and participants
The study protocol has been published elsewhere.9 We undertook this prospective, randomised, double-blind, placebo-controlled, single-centre trial at the Amphia Hospital (Breda, the Netherlands) between May 19, 2010, and June 18, 2013. Eligible patients were 18 years or older, had been diagnosed with COPD according to the guidelines of the Global initiative for chronic Obstructive Lung Disease,10 and had received treatment for three or more exacerbations of COPD in the previous year for which
Results
Figure 1 shows the trial profile. We randomly assigned 92 patients to the azithromycin group (n=47) or the placebo group (n=45), of whom 41 (87%) versus 36 (80%) completed the study. All 92 patients received at least one dose of the assigned treatment (figure 1). In 91 (99%) patients bronchiectasis was excluded by chest CT scan. Table 1 shows baseline characteristics.
We recorded 84 exacerbations in patients in the azithromycin group compared with 129 in those in the placebo group (table 2). 13
Discussion
This study is the first to investigate macrolide treatment in patients with frequent exacerbations of COPD. Our findings show that treatment with azithromycin for 12 months decreased the rate of exacerbations and increased time to first exacerbation compared with placebo (panel).
We examined a COPD population who were refractory to usual care. The proportions of patients who received treatment with inhaled corticosteroids (92%), long-acting beta agonists (LABAs) (93%), and long-acting muscarinic
References (37)
Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases
Lancet Respir Med
(2013)- et al.
The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD
Respir Med
(2005) - et al.
Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy
Pulm Pharmacol Ther
(2010) - et al.
Erythromycin and common cold in COPD
Chest
(2001) - et al.
Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study
Lancet
(2007) - et al.
Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial
Lancet
(2012) - et al.
Factors associated with bronchiectasis in patients with COPD
Chest
(2011) - et al.
Macrolide antibiotics broadly and distinctively inhibit cytokine and chemokine production by COPD sputum cells in vitro
Pharmacol Res
(2011) - et al.
Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality
Thorax
(2012) - et al.
Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease
Thorax
(2005)
Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease
Am J Respir Crit Care Med
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease
Thorax
Mechanisms of action and clinical application of macrolides as immunomodulatory medications
Clin Microbiol Rev
Azithromycin for prevention of exacerbations of COPD
N Engl J Med
Antibiotic prevention of acute exacerbations of COPD
N Engl J Med
Influence of macrolide maintenance therapy and bacterial colonisation on exacerbation frequency and progression of COPD (COLUMBUS): study protocol for a randomised controlled trial
Trials
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary
Am J Respir Crit Care Med
Clinical microbiology procedures handbook
Cited by (215)
Chronic obstructive pulmonary disease and the airway microbiome: A review for clinicians
2024, Respiratory MedicineAzithromycin reduces hemoglobin-induced innate neuroimmune activation
2024, Experimental NeurologyProspects for macrolide therapy of asthma and COPD
2023, Advances in PharmacologyChronic Bronchial Infection in Stable COPD
2023, Open Respiratory Archives
- †
Joint last authors